Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11989016 | 0.84 | TSHR (0.33) | TSHR | |
| SCHEMBL11989015 | 0.83 | TP53 (0.31) | — | |
| SCHEMBL14088242 | 0.83 | — | — | |
| SCHEMBL20254907 | 0.82 | TSHR (0.40) | TSHR | |
| SCHEMBL18651184 | 0.81 | — | — | |
| SCHEMBL10019281 | 0.81 | — | — | |
| SCHEMBL13235922 | 0.79 | — | — | |
| SCHEMBL20920333 | 0.79 | — | — | |
| SCHEMBL18651059 | 0.77 | TSHR (0.31) | TSHR | |
| SCHEMBL20697436 | 0.75 | MAPT (0.44) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9011918-B2 | Biocompatible and biodegradable elastomeric polymers | EVONIK CORPORATION (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140187810-A1 | STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME | ACTELION PHARMACEUTICALS, LTD. (CH) | 2014-07-03 | — | — | US | disclosed |
| US-20130184243-A1 | COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF TREATING SKIN DISORDERS THEREWITH | CEPTARIS THERAPEUTICS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20120301518-A1 | BIOCOMPATIBLE AND BIODEGRADABLE ELASTOMERIC POLYMERS | EVONIK OPERATIONS GMBH (DE) | 2012-11-29 | — | — | US | disclosed |
| US-8246991-B2 | Biocompatible and biodegradable elastomeric polymers | SURMODICS PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120157545-A1 | METHODS FOR TREATING SKIN DISORDERS WITH TOPICAL NITROGEN MUSTARD COMPOSITIONS | ACTELION PHARMACEUTICALS, LTD. (CH) | 2012-06-21 | — | — | US | disclosed |
| US-20110039943-A1 | METHODS FOR TREATING SKIN DISORDERS WITH TOPICAL NITROGEN MUSTARD COMPOSITIONS | ACTELION PHARMACEUTICALS, LTD. (CH) | 2011-02-17 | — | — | US | disclosed |
| US-20100003305-A1 | BIOCOMPATIBLE AND BIODEGRADABLE ELASTOMERIC POLYMERS | EVONIK OPERATIONS GMBH (DE) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120301518-A1 | BIOCOMPATIBLE AND BIODEGRADABLE ELASTOMERIC POLYMERS | ECPAS, FN1, DDR1 | TSHR 3155/4885 |
| US-20110039943-A1 | METHODS FOR TREATING SKIN DISORDERS WITH TOPICAL NITROGEN MUSTARD COMPOSITIONS | S100A8, CUTA, S100A4 | TSHR 4799/4885 |
| US-20130184243-A1 | COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF TREATING SKIN DISORDERS THEREWITH | MGMT, UNG, OGG1 | TSHR 4712/4885 |
| US-20100003305-A1 | BIOCOMPATIBLE AND BIODEGRADABLE ELASTOMERIC POLYMERS | ECPAS, FN1, DDR1 | TSHR 3155/4885 |
| US-20140187810-A1 | STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME | MGMT, UNG, ERCC5 | TSHR 4791/4885 |
| US-20120157545-A1 | METHODS FOR TREATING SKIN DISORDERS WITH TOPICAL NITROGEN MUSTARD COMPOSITIONS | S100A8, CUTA, S100A4 | TSHR 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.